Since October 2010, the Cancer Drugs Fund has helped over 38,000 patients in England to access the life-extending or life improving cancer drugs their clinicians think they need. On 28 September 2013, the Government announced that a further £400 million will be made available to extend the fund to the end of March 2016. The National Institute for Health and Care Excellence (NICE) provides advice to the national health service on the clinical and cost-effectiveness of drugs and treatments. NHS commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance. NICE can apply flexibility in the appraisal of end-of-life treatments for terminal illnesses, including cancers affecting small numbers of patients. The new pricing arrangements for NHS branded medicines, detailed in the 2014 Pharmaceutical Price Regulation Scheme, will also help to ensure that patients will continue to benefit from new discoveries and better medicines.